Literature DB >> 10843768

TH(1)- and TH(2)-TYPE cytokine expression by activated t lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus.

R A Tripp1, D Moore, L J Anderson.   

Abstract

RSV is an important cause of lower respiratory tract illness in infants and the elderly worldwide. The components involved in immunity and those that contribute to inflammation of RSV-induced disease are not clearly understood. To address the relationship between activation antigen and cytokine expression, intracellular levels of IL-2, IL-4, IL-5 and IFN-gamma were determined for CD3, CD44, CD49d, CD54, CD62L and CD102 lymphocytes from the bronchoalveolar lavage and spleen. To examine activation at the DNA level, lymphocytes expressing IL-2, IL-4, IL-5 or IFN-gamma were analysed for G2+M DNA content or phosphatidylserine expression (apoptosis). Trafficking of lymphocytes to the BAL was detected at day 5 p.i., peaked day 7 p.i., and predominately involved CD54(+)and CD102(+)lymphocytes expressing high levels of IL-2, IL-4, IL-5 and IFN-gamma. Lymphocytes expressing CD44(+), CD49d(+)and CD62L(lo)were also observed, however they expressed these cytokines to a lesser extent. DNA analysis of lymphocytes expressing IL-2 or IFN-gamma revealed higher G2'M levels compared to lymphocytes expressing IL-4 or IL-5, suggesting greater activation of Th(1)-type lymphocytes in the lung. These data demonstrate that RSV-induced pulmonary inflammation involves extensive cellular activation and cytokine expression, particularly by CD54(+)and CD102(+)lymphocytes in the lung. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843768     DOI: 10.1006/cyto.1999.0615

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  11 in total

1.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.

Authors:  Sihyug Jang; Joost Smit; Lara E Kallal; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2013-01-04       Impact factor: 4.962

3.  T cell cytokine profiles in childhood asthma.

Authors:  V Brown; T J Warke; M D Shields; M Ennis
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

4.  Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.

Authors:  Sandra Fuentes; Elizabeth M Coyle; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

5.  Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein.

Authors:  J Schwarze; U Schauer
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

Review 6.  The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Authors:  Christine M Oshansky; Wenliang Zhang; Elizabeth Moore; Ralph A Tripp
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

Review 7.  New immune pathways from chronic post-viral lung disease.

Authors:  Loralyn A Benoit; Michael J Holtzman
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

8.  Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin.

Authors:  Matthew T Stier; Melissa H Bloodworth; Shinji Toki; Dawn C Newcomb; Kasia Goleniewska; Kelli L Boyd; Marc Quitalig; Anne L Hotard; Martin L Moore; Tina V Hartert; Baohua Zhou; Andrew N McKenzie; R Stokes Peebles
Journal:  J Allergy Clin Immunol       Date:  2016-04-09       Impact factor: 10.793

9.  Notch ligand Delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines.

Authors:  Matthew A Schaller; Rupak Neupane; Brian D Rudd; Steven L Kunkel; Lara E Kallal; Pamela Lincoln; John B Lowe; Yunfang Man; Nicholas W Lukacs
Journal:  J Exp Med       Date:  2007-11-06       Impact factor: 14.307

Review 10.  Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis.

Authors:  Ralph A Tripp
Journal:  Immune Netw       Date:  2013-10-26       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.